

Generics in Japan

List of Tables

- 1.1 Key Financials of Innovator Pharma Companies
- 1.2 Superior Returns from Global Japanese Companies
- 1.3 Japanese Companies' Cash Positions with Recent Acquisitions
- 1.4 Generic Market Share – WW
- 1.5 Foreign Generic Players in Japan
- 1.6 Financial Summary - Four Major Drug Retail Companies in Japan
- 1.7 Key Financials of Three Major Wholesalers
- 1.8 Distribution Channel Break Down
- 1.9 Biosimilars Guidelines Development in Japan
- 1.10 Degree and Impact of Price Cut on Major Brands
- 2.1 Financial Cost to SHSS in FY 09 Budget
- 2.2 Central Govt.- Heavy Financial Burden
- 2.3 Main Health Insurance Programs
- 2.4 Drug Cost - Target to Reduce National Healthcare Expenditure
- 2.5 National Medical Expenditure
- 2.6 Medical Expenditure - Elderly Patients
- 2.7 International Comparison of Drug Expenditure Ratios
- 3.1 Historical Milestones in Generic Drug Usage in Japan
- 3.2 Impact of 2008 Drug Price Revision in Japan
- 3.3 Data Exclusivity in Japan
- 4.1 The New Layers of Reforms
- 4.2 Revised Patient Co-payment Ratios
- 4.3 Nihou Chouzai - Prescriptions Received between 1st & 6th April'08
- 4.4 Financial Incentives for Pharmacies
- 4.5 Expected Consolidated Impact of Reforms on Generics Promotion
- 5.1 Illustrative Example of Towa's Fair Pricing Strategy
- 5.2 Distribution Channel Sales Breakdown
- 5.3 New Product Launches - Past and Future
- 5.4 Income Statement - Towa
- 5.5 Income Statement - Nippon Chemiphar
- 5.6 Sales Break Up – Nippon Chemiphar
- 5.7 Product Launch and Sales Trend - Sawai
- 5.8 Sales Break Up - Sawai
- 5.9 Income Statement – Sawai
- 5.10 Takeda – Long Listed Products Sales Projections
- 5.11 Takeda – Key Products Patent Status
- 5.12 Astellas – Long Listed Products Sales Projections
- 5.13 Astellas – Key Products Patent Status
- 5.14 Daiichi Sankyo – Long Listed Products Sales Projections
- 5.15 Daiichi Sankyo – Key Products Patent Status
- 5.16 Eisai – Long Listed Products Sales Projections
- 5.17 Eisai – Key Products Patent Status
- 5.18 Mitsubishi Tanabe - Long Listed Products Sales Projections
- 5.19 Mitsubishi Tanabe– Key Products Patent Status
- 5.20 Chugai - Long Listed Products Sales Projections
- 5.21 Chugai– Key Products Patent Status
- 5.22 Shionogi - Long Listed Products Sales Projections

- 5.23 Shionogi– Key Products Patent Status
- 5.24 Dainippon Sumitomo - Long Listed Products Sales Projections
- 5.25 Dainippon Sumitomo– Key Products Patent Status
- 5.26 Kyowa Hakko - Long Listed Products Sales Projections
- 5.27 Kyowa Hakko - Key Products Patent Status
- 5.28 Kyorin - Long Listed Products Sales Projections
- 5.29 Kyorin - Key Products Patent Status
- 5.30 Financial Efficiency Ratios
- 5.31 Relative Key Turnover Ratios
- 5.32 Generic Companies Valuation Summary
- 5.33 Emerging Pharma Markets Growth